Ibandren Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Ibandronic acid

Indications/Uses

Treatment & prevention of postmenopausal osteoporosis.

Click to view Ibandren detailed prescribing information

Dosage/Direction for Use

1 tab once a mth on the same date each mth.

Click to view Ibandren detailed prescribing information

Overdosage

View Ibandren overdosage for action to be taken in the event of an overdose.

Administration

Should be taken on an empty stomach: Take w/ sufficient water (180-240 mL) in the morning, 1 hr before the 1st food/drink/medication/supplement (including Ca antacids or vit) of the day, while standing or sitting in upright position for least 1 hr. Avoid lying down for 1 hr after taking tab.

Contraindications

Hypersensitivity. Incurable hypocalcemia. Patients who are unable to stand or sit upright for at least 1 hr; w/ abnormalities of esophagus which delay esophageal emptying eg, stricture or achalasia. Galactose intolerance, Lapp lactase deficiency & glucose-galactose malabsorption.

Click to view Ibandren detailed prescribing information

Special Precautions

May cause local irritation on the upper GI mucosa; possible irritant effects & potential worsening of the underlying disease. Patients w/ active upper GI problems. Discontinue if dysphagia, odynophagia, retrosternal pain or new or worsening heartburn developed. Treat hypocalcemia & other disturbances of bone & mineral metabolism before starting therapy. Instruct patients to take supplemental Ca & vit D if dietary intake is inadequate. Severe & occasionally incapacitating bone, joint &/or muscle pain; consider discontinuing use if severe symptoms develop. Osteonecrosis of the jaw. Atypical subtrochanteric & diaphyseal femoral fractures. Not recommended in severe renal impairment (CrCl <30 mL/min). Do not take during pregnancy & lactation. Childn <18 yr.

Click to view Ibandren detailed prescribing information

Use In Pregnancy & Lactation

Click to view Ibandren detailed prescribing information

Adverse Reactions

Irritation, inflammation, or ulcers of the esophagus. Hypocalcemia, spasms, twitches or muscle cramps, numbness or tingling in fingers, toes or around the mouth. Severe bone, joint or muscle pain. Osteonecrosis. Unusual thigh bone fractures. Back pain, heartburn, abdominal pain, pain in arms & legs, diarrhea, headache, muscle pain, flu-like symptoms. Allergic reactions eg, hives, difficulty of breathing, swelling of face, lips, tongue or throat, or feeling faint.

Drug Interactions

Interference of absorption w/ products containing Ca including milk & other multivalent cations (eg, Al, Mg, Fe). May cause GI irritation w/ ASA & NSAIDs. Increased gastric pH w/ H2 blockers or PPIs.

Click to view Ibandren detailed prescribing information

Storage

View Ibandren storage conditions for details to ensure optimal shelf-life.

Description

View Ibandren description for details of the chemical structure and excipients (inactive components).

Action

View Ibandren mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Agents Affecting Bone Metabolism

ATC Classification

M05BA06 - ibandronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.

Regulatory Classification

Presentation/Packing

Form

Ibandren FC tab 150 mg

Packing/Price

1's

Ibandren

ibandronic acid

Manufacturer:

Theragen Etex

Distributor:

Oxford Distributions

Marketer:

Bandwell Pharma